Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive developed at IIT Kharagpur in India by Dr. Sujoy K Guha. Phase III clinical trials are underway in India, slowed by insufficient volunteers. It has been patented in India, China, Bangladesh, and the United States. In the United States, there are efforts to get FDA approval under the name Vasalgel.
| Property | Value |
|---|
| dbpedia-owl:abstract
|
- Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive developed at IIT Kharagpur in India by Dr. Sujoy K Guha. Phase III clinical trials are underway in India, slowed by insufficient volunteers. It has been patented in India, China, Bangladesh, and the United States. In the United States, there are efforts to get FDA approval under the name Vasalgel.
- Le RISUG (Reversible Inhibition of Sperm Under Guidance), anciennement dénommé SMA, est le nom de développement d'un contraceptif masculin développé à IIT Kharagpur en Inde par le Docteur Sujoy K Guha. Il est actuellement en phase III des essais cliniques (visant à établir l'efficacité et la tolérance du contraceptif masculin). Ce dernier a été breveté en Inde, en Chine, au Bangladesh, aux États-Unis et au Canada.
|
| dbpedia-owl:wikiPageExternalLink
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Reversible inhibition of sperm under guidance (RISUG), formerly referred to as the synthetic polymer styrene maleic anhydride (SMA), is the development name of a male contraceptive developed at IIT Kharagpur in India by Dr. Sujoy K Guha. Phase III clinical trials are underway in India, slowed by insufficient volunteers. It has been patented in India, China, Bangladesh, and the United States. In the United States, there are efforts to get FDA approval under the name Vasalgel.
- Le RISUG (Reversible Inhibition of Sperm Under Guidance), anciennement dénommé SMA, est le nom de développement d'un contraceptif masculin développé à IIT Kharagpur en Inde par le Docteur Sujoy K Guha. Il est actuellement en phase III des essais cliniques (visant à établir l'efficacité et la tolérance du contraceptif masculin). Ce dernier a été breveté en Inde, en Chine, au Bangladesh, aux États-Unis et au Canada.
|
| rdfs:label
|
- Reversible inhibition of sperm under guidance
- Risug
|
| owl:sameAs
| |
| foaf:page
| |
| is dbpedia-owl:wikiPageRedirects
of | |
| is owl:sameAs
of | |
| is foaf:primaryTopic
of | |
